| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Ginsenoside Rg3 is a key component in how it affects Na+ channels. Inward Na+ peak current (INa) is reversibly inhibited by ginsenoside Rg3 therapy, with a voltage-dependent IC50 of 32.2±4.5 μM [1]. Ginsenoside Rg3 at 100 μM had an average 65% inhibitory effect on hKv1.4 channel current. Ginsenoside Rg3 has reversible and concentration-dependent actions. The Hill coefficient and IC50 value are 1.59±0.13 and 32.6±2.2 μM, respectively[2]. Ginsenoside Rg3 has the ability to dramatically suppress NF-κB activity, which in turn lowers COX-2 expression. In order to assess the cytotoxicity of ginsenoside Rg3 on A549 cells that had been inflamed by IL-1β, the cells were treated for four hours with IL-1β (10 ng/mL) then for twelve hours with ginsenoside Rg3 at doses ranging from 100 to 900 ng/mL. ..H. The MTT assay was used to examine cell viability. When ginsenoside Rg3 was added to IL-1β-induced inflammatory A549 cells, there was no discernible cytotoxicity (Con) as opposed to PBS-treated cells. We investigated A549 cell inflammation to determine the anti-inflammatory effect of ginsenoside Rg3 on inflammation-induced human lung epithelial cells. stimulated by IL-1β (10 ng/mL) and treated with either 900 nM Rg3 or 5 μM dexamethasone (Dex). Western blot analysis was used to assess NF-κB activation in order to assess the impact of ginsenoside Rg3 therapy on A549 cells. Phosphorylated NF-κB p65/total NF-κB p65 densitometry in Rg3-treated cells was much lower than in IL-1β-stimulated inflammatory A549 cells. NF-κB activation is linked to the relevance of Rg3 therapy in lowering the p-p65/p65 ratio. Moreover, COX-2 expression can be successfully downregulated by ginsenoside Rg3 [3].
|
|---|---|
| ln Vivo |
The natural substance ginsenoside Rg3 ((20S)-Rg3) lowers Aβ. For four weeks, APP/PS1 mice received a daily intraperitoneal injection of ginsenoside Rg3 (10 mg/kg/day). Aβ40 and Aβ42 in the brain were significantly reduced after treatment with ginsenoside Rg3, according to an Aβ ELISA assay of brain tissue [4].
|
| References |
|
| Additional Infomation |
(20S)-ginsenoside Rg3 is a ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. It has a role as an apoptosis inducer, an antineoplastic agent, a plant metabolite and an angiogenesis modulating agent. It is a ginsenoside, a tetracyclic triterpenoid and a glycoside. It is functionally related to a (20S)-protopanaxadiol. It derives from a hydride of a dammarane.
Ginsenoside Rg3 has been reported in Panax notoginseng, Panax ginseng, and other organisms with data available. |
| Molecular Formula |
C42H72O13
|
|---|---|
| Molecular Weight |
785.025
|
| Exact Mass |
784.497
|
| CAS # |
14197-60-5
|
| Related CAS # |
(20R)-Ginsenoside Rg3;38243-03-7
|
| PubChem CID |
9918693
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
885.0±65.0 °C at 760 mmHg
|
| Melting Point |
315-318°C
|
| Flash Point |
489.0±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
5.27
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
55
|
| Complexity |
1370
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C
|
| InChi Key |
RWXIFXNRCLMQCD-JBVRGBGGSA-N
|
| InChi Code |
InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
VN 10040; VN10040; Ginsenoside RG3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~127.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2738 mL | 6.3692 mL | 12.7384 mL | |
| 5 mM | 0.2548 mL | 1.2738 mL | 2.5477 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2738 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
